Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Coeptis Therapeutics Holdings, Inc.

Ticker
COEP
Sector
Industry
Report date
May 19, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight the company's strategic merger, capital structure improvements, and ongoing operational initiatives in cryptocurrency mining.

Recent developments:
  • Coeptis completed a business combination with Z Squared, Inc. in April 2026, resulting in a reorganization and name change to Z Squared Inc. [S2].
  • The company announced the extinguishment of a convertible note, strengthening its capital structure in July 2025 [N6].
  • Coeptis filed a Form S-4 registration statement for the proposed merger with Z Squared Inc. in June 2025 [N7].
  • The company secured worldwide rights to the GEAR cell therapy platform and established GEAR Therapeutics to advance cancer cell therapy, though this legacy biopharmaceutical business was spun out in 2026 [N8][S2].
  • OpCo's cryptocurrency mining operations focus on Dogecoin and Litecoin using specialized ASIC miners across multiple U.S. locations, with hosting and custody agreements in place [S2].
Overview

Coeptis Therapeutics Holdings, Inc. underwent a business combination with Z Squared, Inc. in April 2026, resulting in a strategic shift to cryptocurrency mining operations. The company now operates OpCo, a development-stage, vertically integrated digital mining firm focused on Dogecoin and Litecoin. OpCo manages a fleet of specialized ASIC miners deployed across six facilities in North Carolina, South Carolina, and Iowa. The company emphasizes operational efficiency, asset lifecycle management, and rapid conversion of mined assets to fiat currency to mitigate volatility. It maintains key service agreements for hosting and custody and leverages leadership experience in crypto mining and technology sectors. Financially, Coeptis reported modest revenue and significant net losses in Q1 2026, with liquidity ratios reflecting a strong current ratio but low cash ratio. The company faces risks related to competition, capital requirements, and operational execution in a rapidly evolving industry.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Coeptis Therapeutics Holdings, Inc. operates a vertically integrated cryptocurrency mining business focused on Dogecoin and Litecoin mining across multiple U.S. locations. The company completed a significant merger and reorganization in April 2026, shifting its core operations to digital asset mining. It reported $113,771 in revenue and a net loss of $4,020,896 for Q1 2026, with liquidity ratios indicating a current ratio of 3.25 as of March 31, 2026. The business faces competitive, regulatory, and capital-raising risks typical of early-stage mining enterprises.

Scenarios for COEP

Bull case model:

The company's unique focus on altcoin mining, particularly Dogecoin and Litecoin, offers a diversified revenue profile compared to bitcoin-centric miners. Operational efficiencies through specialized hardware management and agile infrastructure deployment could support sustained mining performance. Strategic partnerships and a strong leadership team with relevant industry experience may facilitate effective execution of growth initiatives. The recent extinguishment of convertible notes and capital structure strengthening provide a foundation for pursuing expansion and operational milestones.

Bear case model:

Coeptis operates in a highly competitive and rapidly evolving digital asset mining industry with well-capitalized competitors possessing scale, advanced technology, and access to low-cost renewable energy. The company has a limited operating history and has incurred significant losses, raising concerns about its ability to achieve and sustain profitability. Capital constraints and the need for additional financing pose risks to executing its business plan. Regulatory uncertainties, market volatility, and operational challenges inherent to new enterprises add to the risk profile.

Moat:

Coeptis' competitive advantages stem from its altcoin-focused mining strategy, which allows dynamic allocation of hash power to optimize returns across Dogecoin and Litecoin. Its operational expertise includes advanced repair and spare parts programs that extend hardware life and reduce capital expenditure. The company benefits from strategic hosting and custody agreements, providing stable infrastructure and security. Leadership with proven experience in crypto mining and technology enhances operational agility. These factors collectively contribute to a differentiated position in a competitive and capital-intensive digital asset mining industry.

Risks overview
Risks summary
The primary risk for Coeptis is its capital and liquidity position, which creates substantial doubt about its ability to continue operations without securing additional funding, compounded by competitive and operational challenges in the evolving cryptocurrency mining industry.
Risks details:

• Capital and Liquidity Risk: The company has incurred significant losses and has substantial doubt about its ability to continue as a going concern without additional financing. Access to capital on acceptable terms is uncertain and may dilute existing shareholders or impose restrictive covenants.
• Competitive Risk: The digital asset mining industry is intensely competitive with well-capitalized, technologically advanced, and geographically diversified competitors. These competitors benefit from economies of scale, renewable energy access, and proprietary technology.
• Operational Risk: As a development-stage company, Coeptis faces risks related to executing its business plan, managing growth, and maintaining operational efficiency across multiple mining sites and hardware fleets.
• Regulatory and Market Risk: The company operates in a highly regulated environment with exposure to cryptocurrency market volatility, regulatory changes, and accounting standards that affect asset valuation and reporting.

FINAL FORECAST FOR COEP

Final take one line
Coeptis Therapeutics Holdings, Inc. operates a development-stage cryptocurrency mining business with high visibility into its operations, financials, and risks following a recent merger and strategic shift.
Final take 12 to 24 month view

Business trends: Transition to altcoin-focused cryptocurrency mining with operational emphasis on Dogecoin and Litecoin, leveraging specialized hardware and agile infrastructure.
Execution milestones: Completion of merger with Z Squared, establishment of hosting and custody agreements, fleet deployment across multiple U.S. sites, and capital structure strengthening.
Key risks: Capital and liquidity constraints, intense competition from well-capitalized miners, operational execution challenges, and regulatory and market uncertainties.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Coeptis Therapeutics Holdings, Inc. completed a business combination (Merger) with Z Squared, Inc. on April 24, 2026, resulting in a reorganization and spin-out of its historical biopharmaceutical operations except those conducted through GEAR Therapeutics, Inc. [S1][S2].
  • Post-merger, Coeptis changed its name to Z Squared Inc. on April 27, 2026 [S1][S2].
  • The company operates a development-stage, vertically integrated cryptocurrency mining business (OpCo) focused on optimized, multi-asset digital mining of Dogecoin (DOGE) and Litecoin (LTC) across six locations in North Carolina, South Carolina, and Iowa [S1][S2].
  • OpCo manages a fleet of specialized ASIC miners including Antminer L7, L9, and DG1+ models, tailored to specific mining algorithms such as SHA-256, Scrypt, and kHeavyHash [S1][S2].
  • Mining operations emphasize prompt conversion of mined crypto assets to fiat or stablecoins within approximately two weeks to mitigate price volatility and comply with accounting standards [S1][S2].
  • The company has a Master Services Agreement with Minting Dome for hosting, power at $0.088 per kWh, internet access, and operational management of mining equipment, with an initial term of three years [S1][S2].
  • OpCo also has a custody agreement with Anchorage Digital for secure storage and settlement of digital assets [S1][S2].
  • Competitive advantages include an altcoin-focused mining strategy, operational expertise, agile infrastructure management, and advanced repair and lifecycle management processes to extend hardware longevity and reduce capital waste [S1][S2].
  • Leadership includes Michelle Burke as Co-Chief Executive Officer since April 2026, with prior experience leading crypto mining and technology companies [S1][S2].
  • The company reported revenue of $113,771 and a net loss of $4,020,896 for the quarter ended March 31, 2026, with basic and diluted EPS of -$0.65 [S2].
  • As of March 31, 2026, Coeptis held cash and equivalents of $13,830 and short-term investments of $50,551, with current assets of $5,908,108 and current liabilities of $1,817,319, resulting in a current ratio of 3.25 and a cash ratio of 0.04 [S2].
  • The company has incurred significant losses historically and expects to require additional capital to fund operations and growth initiatives; there is substantial doubt about its ability to continue as a going concern without additional financing [S1][S2].
  • Risks include intense competition in the digital asset mining industry from well-capitalized and technologically advanced firms, regulatory and market uncertainties, capital constraints, and operational risks associated with new enterprise growth [S1][S2].
  • The company has entered into various strategic partnerships and agreements, including licensing for cell therapy platforms and AI-driven marketing solutions, but its current core business focus is on cryptocurrency mining post-merger [N6][N7][N8].
  • Recent news includes the extinguishment of a convertible note strengthening capital structure and filings related to the merger with Z Squared Inc. [N6][N7].
Sources
Sources - Context summary

Generated 2026-05-19

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-19 | 10-K
  • S2 | 2026-05-14 | 10-Q
Sources - News headlines
  • N1 | 2026-05-19 | www.nasdaq.com | Stocks Settle Mixed as Iran War Remains Unresolved | https://www.nasdaq.com/articles/stocks-settle-mixed-iran-war-remains-unresolved
  • N2 | 2026-05-19 | www.nasdaq.com | Bank Leumi Q1 Earnings Fall | https://www.nasdaq.com/articles/bank-leumi-q1-earnings-fall
  • N3 | 2026-05-19 | www.nasdaq.com | Wheat Rally Pushing Higher on US/China Fact Sheet Trade Numbers | https://www.nasdaq.com/articles/wheat-rally-pushing-higher-us-china-fact-sheet-trade-numbers
  • N4 | 2026-05-19 | www.nasdaq.com | Gossamer Bio Q1 Net Loss Expands; Eyes On The Pre-NDA Meeting With FDA For Seralutinib W In Mid-June | https://www.nasdaq.com/articles/gossamer-bio-q1-net-loss-expands-eyes-pre-nda-meeting-fda-seralutinib-w-mid-june
  • N5 | 2026-05-19 | www.nasdaq.com | Allegiant Air Announces Eight New Non-Stop Routes To Florida | https://www.nasdaq.com/articles/allegiant-air-announces-eight-new-non-stop-routes-florida
  • N6 | 2025-07-22 | www.nasdaq.com | Coeptis Therapeutics Holdings, Inc. Announces Extinguishment of Convertible Note, Strengthening Capital Structure | https://www.nasdaq.com/articles/coeptis-therapeutics-holdings-inc-announces-extinguishment-convertible-note-strengthening
  • N7 | 2025-06-26 | www.nasdaq.com | Coeptis Therapeutics Files Form S-4 Registration Statement for Proposed Merger with Z Squared Inc. | https://www.nasdaq.com/articles/coeptis-therapeutics-files-form-s-4-registration-statement-proposed-merger-z-squared-inc
  • N8 | 2025-05-28 | www.nasdaq.com | SNAP Biosciences and Monarch Therapeutics Announce Licensing Agreement for Next-Generation NK Cell Therapy Development | https://www.nasdaq.com/articles/snap-biosciences-and-monarch-therapeutics-announce-licensing-agreement-next-generation-nk
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine